"Are you familiar with the term "triple agonist"? If you aren't now, it might be one to file away for later use, in much the same way that GLP-1 has entered into the broader lexicon. (Actually, there's another reason to associate these two terms, but we'll get to that shortly.) This week, the pharmaceutical company Eli Lilly shared the results of a Phase 3 clinical trial for the drug retatrutide, which is used to treat patients with both obesity and knee osteoarthritis."
"Eli Lilly's announcement of the results describes this drug as a "GIP, GLP-1 and glucagon triple hormone receptor agonist" which is used to both spark weight loss and reduce pain in the people taking it. As Gina Kolata of The New York Times explained, this new drug is "sort of a souped-up GLP-1" which addresses three different types of hormones."
Retatrutide is described as a GIP, GLP-1 and glucagon triple hormone receptor agonist aimed at inducing weight loss and reducing pain in patients with obesity and knee osteoarthritis. In a Phase 3 trial, 58.6% of participants receiving the higher dose achieved at least 25% weight loss and 23.7% achieved at least 35% weight loss, alongside increased physical function and a significant reduction in pain. Additional Phase 3 readouts are expected, with seven more due in 2026. Detailed trial data will be published in a scientific journal. The mechanistic basis for greater weight-loss potency when expanding hormonal targets remains to be clarified.
Read at InsideHook
Unable to calculate read time
Collection
[
|
...
]